Insulet Corp. PODD
NASDAQ · Healthcare · Medical - Devices
$133.17
Close on Fri, 20 Nov 2026 · market value $9.2B
What the price is betting on
In line with its recordAt $133, the price assumes revenue grows about 16% a year for five years, from $3.2B to about $6.1B by FY2030. That is about one and a half times what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 9.2% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than PODD? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$88
Base
$119
Bull
$160
Today $133
- Bear $88. Growth cools well below the recent pace, and the FY2025 earnings drop proves to be a trend, not a blip. Gross margin gains do not reach operating profit, MiniMed and Beta Bionics erode share or pricing on a business that is almost all one product line, and the pending pharmacy benefit manager contracts bring weaker terms or are delayed.
- Base $119. Cash flow grows quickly from a depressed trailing level as management's guided margin expansion shows up in filed results, then fades toward the long run. The two remaining pharmacy benefit manager contracts close without hurting terms. Earnings recover only gradually from the FY2025 drop, and new entrants take some share but do not break the growth.
- Bull $160. Automated insulin delivery stays a very fast growing, underpenetrated segment and Insulet keeps taking share with its Omnipod products. All three 2027 pharmacy benefit manager contracts close on good terms, the guided margin expansion arrives in filed results, and new entrants do not cut prices enough to stop cash flow compounding from the stronger FY2025 level.
AI-written stories, valued by code from the same model.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$3.3B$3.3B, on the path
- FY2027$3.9B$3.7B, below the path
- FY2028$4.5B$4.1B, below the path
- FY2029$5.2B$4.6B, below the path
- FY2030$6.1B$5B, below the path
Each year's revenue at 16% growth from $3.2B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Devices · listed on NASDAQ
- Revenue, FY2025
- $2.7B
- Growth, 3 years a year
- 26%
- Cash margin
- 14%
- Net debt
- $335M
- Shares, 3-year change
- +2.8%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.